We have recently updated our Privacy Policy to include information regarding the cookies we collect. By continuing to use this website you agree to our Privacy Policy and Terms of Use.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 1, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the addition of Barry Greene
Thinking differently about thinking – Development plans for SAGE-718 focused on executive function across multiple indications Early learnings from studies of other compounds created multi-faceted insights for SAGE-324 program in essential tremor Interview with investigator from SHORELINE study
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 1, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 20, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that it will host Sage
Pipeline progress continues with first patient dosed and ongoing enrollment in multiple clinical trials across the depression and neurology franchises Durability of response was observed in patients with MDD who responded to a 2-week treatment with zuranolone in MOUNTAIN Study six-month follow-up
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 30, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 21, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 1, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at
Expected initiation of three new short-term zuranolone clinical studies in 2020, with the potential for three distinct indications April restructuring to advance corporate strategy and pipeline expected to result in approximate annualized cost savings of $170M , with significant portion related to